252 related articles for article (PubMed ID: 25230786)
1. Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.
Abdel-Rahman O
Tumour Biol; 2014 Nov; 35(11):10615-25. PubMed ID: 25230786
[TBL] [Abstract][Full Text] [Related]
2. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Mateo J; Heymach JV; Zurita AJ
Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
[TBL] [Abstract][Full Text] [Related]
3. Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms.
Berardi R; Torniai M; Partelli S; Rubini C; Pagliaretta S; Savini A; Polenta V; Santoni M; Giampieri R; Onorati S; Barucca F; Murrone A; Bianchi F; Falconi M
PLoS One; 2018; 13(5):e0197035. PubMed ID: 29787601
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
Abdel-Rahman O; Fouad M
J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
[TBL] [Abstract][Full Text] [Related]
5. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
6. Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms.
Ohmoto A; Morizane C
Curr Drug Targets; 2020; 21(4):389-405. PubMed ID: 31633473
[TBL] [Abstract][Full Text] [Related]
7. Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms.
Grillo F; Florio T; Ferraù F; Kara E; Fanciulli G; Faggiano A; Colao A;
Endocr Relat Cancer; 2018 Sep; 25(9):R453-R466. PubMed ID: 29769293
[TBL] [Abstract][Full Text] [Related]
8. Everolimus-based combination for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): biological rationale and critical review of published data.
Abdel-Rahman O; Fouad M
Tumour Biol; 2015 Feb; 36(2):467-78. PubMed ID: 25596701
[TBL] [Abstract][Full Text] [Related]
9. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors.
Raymond E; Hobday T; Castellano D; Reidy-Lagunes D; García-Carbonero R; Carrato A
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():19-26. PubMed ID: 21308478
[TBL] [Abstract][Full Text] [Related]
10. Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications.
Vitale G; Cozzolino A; Malandrino P; Minotta R; Puliani G; Saronni D; Faggiano A; Colao A
Front Endocrinol (Lausanne); 2021; 12():665631. PubMed ID: 33935975
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: from bench to bedside.
Cella CA; Minucci S; Spada F; Galdy S; Elgendy M; Ravenda PS; Zampino MG; Murgioni S; Fazio N
Cancer Treat Rev; 2015 Nov; 41(9):754-60. PubMed ID: 26142874
[TBL] [Abstract][Full Text] [Related]
12. Variability of the Ki-67 proliferation index in gastroenteropancreatic neuroendocrine neoplasms - a single-center retrospective study.
Shi H; Zhang Q; Han C; Zhen D; Lin R
BMC Endocr Disord; 2018 Jul; 18(1):51. PubMed ID: 30055596
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatment of neuroendocrine tumors with hepatic metastases.
Demirkan BH; Eriksson B
Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine tumor disease: an evolving landscape.
Frilling A; Akerström G; Falconi M; Pavel M; Ramos J; Kidd M; Modlin IM
Endocr Relat Cancer; 2012 Oct; 19(5):R163-85. PubMed ID: 22645227
[TBL] [Abstract][Full Text] [Related]
15. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
[TBL] [Abstract][Full Text] [Related]
16. Preclinical drug studies in MEN1-related neuroendocrine neoplasms (MEN1-NENs).
Grozinsky-Glasberg S; Lines KE; Avniel-Polak S; Bountra C; Thakker RV
Endocr Relat Cancer; 2020 Sep; 27(9):R345-R355. PubMed ID: 32590358
[TBL] [Abstract][Full Text] [Related]
17. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications.
Lauricella E; Mandriani B; Cavallo F; Pezzicoli G; Chaoul N; Porta C; Cives M
Front Oncol; 2022; 12():957068. PubMed ID: 36059642
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
Weber MM; Fottner C
Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.
Khasraw M; Yap SY; Ananda S
Expert Rev Anticancer Ther; 2013 Apr; 13(4):451-9. PubMed ID: 23560839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
